Nxera Pharma revises 2026 forecast after global license deal with AbbVie
FROM THE WIRE · FINANCE.YAHOO.COM
Nxera Pharma Tokyo, Japan and Cambridge, UK, 4 November 2026 – Nxera Pharma Co., Ltd. ("Nxera" or the "Company") today announces that it has revised its consolidated financial forecast for the year ending 31 December 2026, previously announced on 13 February 2026, as set out…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishThe forecast revision is tied to a licensing deal that could generate revenue for Nxera.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Nxera revises its consolidated forecast for the year ending 31 December 2026.
- 02Forecast net sales move to 48,800 million yen, the top of the previous range.
- 03The revision follows an exclusive global license agreement with AbbVie for the EP4 program.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Nxera Pharma Co., Ltd.1,520.00 n/aMarket closedtoday -4.10%Positive AbbVie Inc.286.00 USDMarket closedtoday -0.98%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets